Table 1.
Clinical manifestations of advanced NSCLC patients receiving ICI treatments.
| Characteristics | Cohort 1 anti-PD-1 monotherapy (n = 50) | Cohort 2 anti-PD-1 monotherapy (n = 70) | Cohort 3 anti-PD-L1 monotherapy (n = 30) |
|---|---|---|---|
| Age, year | |||
| Median | 61 | 61 | 62 |
| Sex, n (%) | |||
| Male | 41 (82.0) | 57 (81.4) | 26 (86.7) |
| Female | 9 (18.0) | 13 (18.6) | 4 (13.3) |
| History, n (%) | |||
| Squamous | 17 (34.0) | 23 (32.9) | 12 (40.0) |
| Non-squamous | 33 (66.0) | 47 (67.1) | 18 (60.0) |
| Smoking status, n (%) | |||
| Smoker | 39 (78.0) | 44 (62.9) | 23 (76.7) |
| Nonsmoker | 11 (22.0) | 20 (28.6) | 7 (23.3) |
| Unknown | 0 (0.0) | 6 (8.5) | 0 (0.0) |
| Disease stage, n (%) | |||
| III | 8 (16.0) | 12 (17.1) | 1 (3.3) |
| IV | 42 (84.0) | 58 (82.9) | 29 (96.7) |
| EGFR mutation, n (%) | |||
| Yes | 6 (12.0) | 7 (10.0) | 2 (6.7) |
| No | 37 (74.0) | 44 (62.9) | 28 (93.3) |
| Unknown | 7 (14.0) | 19 (27.1) | 0 (0.0) |
| Treatment, n (%) | |||
| First-line | 0 (0.0) | 19 (27.1) | 15 (50.0) |
| Second-line | 45 (90.0) | 33 (47.1) | 10 (33.3) |
| More than second | 5 (10.0) | 18 (25.8) | 5 (16.7) |
| Response | |||
| R | 17 (34.0) | 24 (34.3) | 15 (50.0) |
| NonR | 33 (66.0) | 46 (65.7) | 15 (50.0) |
| Median PFS (95% CI, days) | 70 (21-119) | 83 (44-122) | 170 (60-280) |